Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Hodge, Greg ^a,b   Jersmann, Hubertus ^a,b   Tran, Hai B ^a   Roscioli, Eugene ^a   Holmes, Mark ^a,b   Reynolds, Paul N ^a,b   Hodge, Sandra ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

CD28nullCD8+ T and NKT like cells; COPD; HDAC2; IFN and TNF ; Lymphocyte senescence

Indexed keywords

CD28 ANTIGEN; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; GRANZYME B; HISTONE DEACETYLASE 2; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; THEOPHYLLINE; TUMOR NECROSIS FACTOR; CYCLOSPORIN; ENZYME ACTIVATOR; HDAC2 PROTEIN, HUMAN; HISTONE ACETYLTRANSFERASE; IFNG PROTEIN, HUMAN;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER T CELL; PROTEIN EXPRESSION; SENESCENCE; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; WESTERN BLOTTING; AGED; BLOOD; CASE CONTROL STUDY; CELL AGING; DOWN REGULATION; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; IMMUNOLOGY; MIDDLE AGED; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADULT; AGED; ANTIGENS, CD28; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELL AGING; CYCLOSPORINE; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME ACTIVATORS; FEMALE; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE 2; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; PHENOTYPE; PREDNISOLONE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THEOPHYLLINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84944679775     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0287-2     Document Type: Article

References (29)

1. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373:1905-17.
2. Barnes PJ, Shapiro SD, Pauwells RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672-88.
3. Hodge G, Nairn J, Holmes M, Reynolds P, Hodge S. Increased intracellular Th1 pro-inflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelieal T cells of COPD subjects. Clin and Exp Immunol. 2007;150:22-9.
4. Hodge S, Hodge G, Nairn J, Holmes M, Reynolds PN. Increased airway granzyme b and perforin in current and ex-smoking COPD subjects. COPD. 2006;3(4):179-87.
5. Hodge G, Mukaro V, Reynolds P, Hodge S. Role of increased CD8/CD28(null) T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease. Clin and Exp Immunol. 2011;166(1):94-102.
6. Morla M, Busquets X, Pons J, Sauleda W, MacNee W, Agusti AGN. Telomere shortening in smokers with and without COPD. Eur Respir J. 2006;27:525-8.
7. Hodge G, Mukaro V, Holmes M, Reynolds P, Hodge S. Enhanced cytotoxic function of natural killer and natural killer T-like cells with associated decreased CD94 (Kp43) in the chronic obstructive pulmonary disease airway. Respirology. 2013;18(2):369-76.
8. Arosa FA. CD8 + CD28-T cells: Certainties and uncertainties of a prevelant human T-cell subset. Immunol Cell Biol. 2002;80:1-13.
9. Hodge G, Holmes M, Jersmann H, Reynolds PN, Hodge S. The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD. Respir Res. 2013;14(1):63.
10. Hodge G, Jersmann H, Tran HB, Holmes M, Reynolds PN, Hodge S. Lymphocyte senescence in COPD is associated with loss of glucocorticoid receptor expression by pro-inflammatory/cytotoxic lymphocytes. Respir Res. 2015;16:2.
11. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung disease. Eur Repir J. 2005;25:552-63.
12. Cosio BG, Tsaprouni L, Kazuhiro I, Jazwari E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004;200:689-95.
13. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Cri Care Med. 2001;163:1256-76.
14. Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J. 2005;25:447-54.
15. Tran HB, Ahern J, Hodge G, Holt P, Dean MM, Reynolds PN, et al. Oxidative stress decreases functional airway mannose binding lectin in COPD. PLoS One. 2014;9:e98571.
16. Ito K, Yamamura S, Essilfe-Quaye S, Cosio B, Ito M, Barnes PJ, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κb suppression. J Exp Med. 2006;1:7-13.
17. Adenuga D, Yao H, March TH, Seagrave J, Rahman I. Histone deacetylase 2 in phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Repir Cell Mol Biol. 2009;40:464-73.
18. Chen Y, Huang P, Ai W, Li K, Guo W, Zhang J, et al. Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD. J Inflamm. 2012;10:10.
19. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967-76.
20. Boucheron N, Tschismarov R, Goesch L, Moser MA, Lagger S, Sakaguchi S, et al. CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2. Nat Immunol. 2014;15:439-48.
21. Kypreou KP, Sourlingas TG, Sekeri-Pataryas KP. Age-dependent response of lymphocytes in the induction of the linker histone variant, H1 degrees of histone H4 acetylation after treatment with histone deacetylase inhibitor, trichostatin A. Exp Gerontol. 2004;39:469-79.
22. Teo FH, de Oliveira RT, Mamoni RL, Ferreira MC, Nadruz W, Coelho OR, et al. Characterisation of CD4 + CD28null T cells in patients with coronary artery disease and individuals with risk factors for artherosclerosis. Cell Immunol. 2013;281:11-9.
23. Thewissen M, Somers V, Hellings N, Fraussen J, Damoiseaux J, Stinissen P. CD4 + CD28null T cells in autoimmune disease: pathologenic features and decreased susceptibility to immunoregulation. J Immunol. 2007;179(10):6514-23.
24. Fasth AE, Snir O, Johansson AA, Nordmark B, Rahbar A, Klint E, et al. Skewed distribution of pro-inflammatory CD4 + CD28null T cells in rheumatoid arthritis. Arthritis Res Ther. 2007;9(5):R87.
25. Yokoyama Y, Fukunaga K, Ikeuchi H, Hamikozuru K, Hida N, Ohda Y, et al. The CD4CD28null and the regulatory CD4 + CD25High T-cell phenotypes in patients with ulcerative colitis during active and quiescent disease, following colectomy. Cytokine. 2011;56(2):466-70.
26. Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev. 2005;205:158-69.
27. Yao H, Rahman I. Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPD. Am J Physiol Lung Cell Mol Physiol. 2012;303:557-66.
28. Ford PA, Durham AL, Russel REK, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010;137:1338-44.
29. Volgelmeier CF. Sytemic steroids in COPD-the beauty and the beast. Resp Res. 2014;15:38.